Top

Published in:

Open Access 01-12-2011 | Review

Selective transmission of R5 HIV-1 variants: where is the gatekeeper?

Authors: Jean-Charles Grivel, Robin J Shattock, Leonid B Margolis

Published in: Journal of Translational Medicine | Special Issue 1/2011

Abstract

To enter target cells HIV-1 uses CD4 and a coreceptor. In vivo the coreceptor function is provided either by CCR5 (for R5) or CXCR4 (for X4 HIV-1). Although both R5 and X4 HIV-1 variants are present in body fluids (semen, blood, cervicovaginal and rectal secretions), R5 HIV-1 appears to transmit infection and dominates early stages of HIV disease. Moreover, recent sequence analysis of virus in acute infection shows that, in the majority of cases of transmission, infection is initiated by a single virus. Therefore, the existence of a “gatekeeper” that selects R5 over X4 HIV-1 and that operates among R5 HIV-1 variants has been suggested. In the present review we consider various routes of HIV-transmission and discuss potential gatekeeping mechanisms associated with each of these routes. Although many mechanisms have been identified none of them explains the almost perfect selection of R5 over X4 in HIV-1 transmission. We suggest that instead of one strong gatekeeper there are multiple functional gatekeepers and that their superimposition is sufficient to protect against X4 HIV-1 infection and potentially select among R5 HIV-1 variants. In conclusion, we propose that the principle of multiple barriers is more general and not restricted to protection against X4 HIV-1 but rather can be applied to other phenomena when one factor has a selective advantage over the other(s). In the case of gatekeepers for HIV-1 transmission, the task is to identify them and to decipher their molecular mechanisms. Knowledge of the gatekeepers‘ localization and function may enable us to enhance existing barriers against R5 transmission and to erect the new ones against all HIV-1 variants.

Alkhatib G, Combadiere C, Broder CC, Feng Y, Kennedy PE, Murphy PM, Berger EA: CC CKR5: a RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1. Science. 1996, 272: 1955-1958. 10.1126/science.272.5270.1955.PubMed

Deng H, Liu R, Ellmeier W, Choe S, Unutmaz D, Burkhart M, Di Marzio P, Marmon S, Sutton RE, Hill CM: Identification of a major co-receptor for primary isolates of HIV-1. Nature. 1996, 381: 661-666. 10.1038/381661a0.PubMed

Dragic T, Litwin V, Allaway GP, Martin SR, Huang Y, Nagashima KA, Cayanan C, Maddon PJ, Koup RA, Moore JP, Paxton WA: HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature. 1996, 381: 667-673. 10.1038/381667a0.PubMed

Berger EA, Doms RW, Fenyo EM, Korber BT, Littman DR, Moore JP, Sattentau QJ, Schuitemaker H, Sodroski J, Weiss RA: A new classification for HIV-1. Nature. 1998, 391: 240-10.1038/34571.PubMed

Moore JP, Kitchen SG, Pugach P, Zack JA: The CCR5 and CXCR4 coreceptors--central to understanding the transmission and pathogenesis of human immunodeficiency virus type 1 infection. AIDS Res Hum Retroviruses. 2004, 20: 111-126. 10.1089/088922204322749567.PubMed

Keele BF, Derdeyn CA: Genetic and antigenic features of the transmitted virus. Curr Opin HIV AIDS. 2009, 4: 352-357. 10.1097/COH.0b013e32832d9fef.PubMed

Salazar-Gonzalez JF, Salazar MG, Keele BF, Learn GH, Giorgi EE, Li H, Decker JM, Wang S, Baalwa J, Kraus MH: Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection. J Exp Med. 2009, 206: 1273-1289. 10.1084/jem.20090378.PubMedCentralPubMed

Vahlne A: A historical reflection on the discovery of human retroviruses. Retrovirology. 2009, 6: 40-10.1186/1742-4690-6-40.PubMedCentralPubMed

Gottlieb MS, Schroff R, Schanker HM, Weisman JD, Fan PT, Wolf RA, Saxon A: Pneumocystis carinii pneumonia and mucosal candidiasis in previously healthy homosexual men: evidence of a new acquired cellular immunodeficiency. N Engl J Med. 1981, 305: 1425-1431. 10.1056/NEJM198112103052401.PubMed

10.

Klatzmann D, Barre-Sinoussi F, Nugeyre MT, Danquet C, Vilmer E, Griscelli C, Brun-Veziret F, Rouzioux C, Gluckman JC, Chermann JC: Selective tropism of lymphadenopathy associated virus (LAV) for helper-inducer T lymphocytes. Science. 1984, 225: 59-63. 10.1126/science.6328660.PubMed

11.

Popovic M, Read-Connole E, Gallo RC: T4 positive human neoplastic cell lines susceptible to and permissive for HTLV-III. Lancet. 1984, 2: 1472-1473. 10.1016/S0140-6736(84)91666-0.PubMed

12.

Klatzmann D, Champagne E, Chamaret S, Gruest J, Guetard D, Hercend T, Gluckman JC, Montagnier L: T-lymphocyte T4 molecule behaves as the receptor for human retrovirus LAV. Nature. 1984, 312: 767-768. 10.1038/312767a0.PubMed

13.

Maddon PJ, Dalgleish AG, McDougal JS, Clapham PR, Weiss RA, Axel R: The T4 gene encodes the AIDS virus receptor and is expressed in the immune system and the brain. Cell. 1986, 47: 333-348. 10.1016/0092-8674(86)90590-8.PubMed

14.

Chesebro B, Buller R, Portis J, Wehrly K: Failure of human immunodeficiency virus entry and infection in CD4-positive human brain and skin cells. Journal of virology. 1990, 64: 215-221.PubMedCentralPubMed

15.

McDougal JS, Klatzmann DR, Maddon PJ: CD4-gp120 interactions. Curr Opin Immunol. 1991, 3: 552-558. 10.1016/0952-7915(91)90020-2.PubMed

16.

Benn S, Rutledge R, Folks T, Gold J, Baker L, McCormick J, Feorino P, Piot P, Quinn T, Martin M: Genomic heterogeneity of AIDS retroviral isolates from North America and Zaire. Science. 1985, 230: 949-951. 10.1126/science.2997922.PubMed

17.

Hahn BH, Gonda MA, Shaw GM, Popovic M, Hoxie JA, Gallo RC, Wong-Staal F: Genomic diversity of the acquired immune deficiency syndrome virus HTLV-III: different viruses exhibit greatest divergence in their envelope genes. Proc Natl Acad Sci U S A. 1985, 82: 4813-4817. 10.1073/pnas.82.14.4813.PubMedCentralPubMed

18.

Wong-Staal F, Shaw GM, Hahn BH, Salahuddin SZ, Popovic M, Markham P, Redfield R, Gallo RC: Genomic diversity of human T-lymphotropic virus type III (HTLV-III). Science. 1985, 229: 759-762. 10.1126/science.2992084.PubMed

19.

di Marzo Veronese F, Sarngadharan MG, Rahman R, Markham PD, Popovic M, Bodner AJ, Gallo RC: Monoclonal antibodies specific for p24, the major core protein of human T-cell leukemia virus type III. Proc Natl Acad Sci U S A. 1985, 82: 5199-5202. 10.1073/pnas.82.15.5199.PubMedCentralPubMed

20.

Brun-Vezinet F, Rouzioux C, Barre-Sinoussi F, Klatzmann D, Saimot AG, Rozenbaum W, Christol D, Gluckmann JC, Montagnier L, Chermann JC: Detection of IgG antibodies to lymphadenopathy-associated virus in patients with AIDS or lymphadenopathy syndrome. Lancet. 1984, 1: 1253-1256. 10.1016/S0140-6736(84)92444-9.PubMed

21.

Palker TJ, Scearce RM, Miller SE, Popovic M, Bolognesi DP, Gallo RC, Haynes BF: Monoclonal antibodies against human T cell leukemia-lymphoma virus (HTLV) p24 internal core protein. Use as diagnostic probes and cellular localization of HTLV. J Exp Med. 1984, 159: 1117-1131. 10.1084/jem.159.4.1117.PubMed

22.

Schupbach J, Haller O, Vogt M, Luthy R, Joller H, Oelz O, Popovic M, Sarngadharan MG, Gallo RC: Antibodies to HTLV-III in Swiss patients with AIDS and pre-AIDS and in groups at risk for AIDS. N Engl J Med. 1985, 312: 265-270. 10.1056/NEJM198501313120502.PubMed

23.

Barrett JE, Dawson G, Heller J, Bairstow C, Fico R, Webber JS, Gutierrez R, Decker RH: Performance evaluation of the Abbott HTLV III EIA, a test for antibody to HTLV III in donor blood. Am J Clin Pathol. 1986, 86: 180-185.PubMed

24.

Gallo D, Diggs JL, Shell GR, Dailey PJ, Hoffman MN, Riggs JL: Comparison of detection of antibody to the acquired immune deficiency syndrome virus by enzyme immunoassay, immunofluorescence, and Western blot methods. J Clin Microbiol. 1986, 23: 1049-1051.PubMedCentralPubMed

25.

Jackson B, Sannerud K, Rhame F, Tsang R, Balfour HH: Comparison of reverse transcriptase assay with the Retro-Tek viral capture assay for detection of human immunodeficiency virus. Diagn Microbiol Infect Dis. 1987, 7: 185-192. 10.1016/0732-8893(87)90003-4.PubMed

26.

Kaplan MH, Pahwa SG, Popovic M, Sarngadharan MG, Gallo RC: A classification of HTLV-III infection based on 75 cases seen in a suburban community. Cancer Res. 1985, 45: 4655s-4658s.PubMed

27.

Asjo B, Morfeldt-Manson L, Albert J, Biberfeld G, Karlsson A, Lidman K, Fenyo EM: Replicative capacity of human immunodeficiency virus from patients with varying severity of HIV infection. Lancet. 1986, 2: 660-662.PubMed

28.

Cheng-Mayer C, Seto D, Tateno M, Levy JA: Biologic features of HIV-1 that correlate with virulence in the host. Science. 1988, 240: 80-82. 10.1126/science.2832945.PubMed

29.

Castro BA, Cheng-Mayer C, Evans LA, Levy JA: HIV heterogeneity and viral pathogenesis. Aids. 1988, 2 (Suppl 1): S17-27. 10.1097/00002030-198800001-00004.PubMed

30.

Sakai K, Dewhurst S, Ma XY, Volsky DJ: Differences in cytopathogenicity and host cell range among infectious molecular clones of human immunodeficiency virus type 1 simultaneously isolated from an individual. J Virol. 1988, 62: 4078-4085.PubMedCentralPubMed

31.

Fredriksson R, Stalhanske P, von Gegerfelt A, Lind B, Aman P, Rassart E, Fenyo EM: Biological characterization of infectious molecular clones derived from a human immunodeficiency virus type-1 isolate with rapid/high replicative capacity. Virology. 1991, 181: 55-61. 10.1016/0042-6822(91)90469-R.PubMed

32.

Fernandez-Larsson R, Srivastava KK, Lu S, Robinson HL: Replication of patient isolates of human immunodeficiency virus type 1 in T cells: a spectrum of rates and efficiencies of entry. Proc Natl Acad Sci U S A. 1992, 89: 2223-2226. 10.1073/pnas.89.6.2223.PubMedCentralPubMed

33.

De Rossi A, Giaquinto C, Ometto L, Mammano F, Zanotto C, Dunn D, Chieco-Bianchi L: Replication and tropism of human immunodeficiency virus type 1 as predictors of disease outcome in infants with vertically acquired infection. J Pediatr. 1993, 123: 929-936. 10.1016/S0022-3476(05)80389-0.PubMed

34.

Scarlatti G, Hodara V, Rossi P, Muggiasca L, Bucceri A, Albert J, Fenyo EM: Transmission of human immunodeficiency virus type 1 (HIV-1) from mother to child correlates with viral phenotype. Virology. 1993, 197: 624-629. 10.1006/viro.1993.1637.PubMed

35.

Lifson JD, Reyes GR, McGrath MS, Stein BS, Engleman EG: AIDS retrovirus induced cytopathology: giant cell formation and involvement of CD4 antigen. Science. 1986, 232: 1123-1127. 10.1126/science.3010463.PubMed

36.

Epstein LG, Sharer LR, Cho ES, Myenhofer M, Navia B, Price RW: HTLV-III/LAV-like retrovirus particles in the brains of patients with AIDS encephalopathy. AIDS Res. 1984, 1: 447-454.PubMed

37.

Tersmette M, de Goede RE, Al BJ, Winkel IN, Gruters RA, Cuypers HT, Huisman HG, Miedema F: Differential syncytium-inducing capacity of human immunodeficiency virus isolates: frequent detection of syncytium-inducing isolates in patients with acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. J Virol. 1988, 62: 2026-2032.PubMedCentralPubMed

38.

Fenyo EM, Morfeldt-Manson L, Chiodi F, Lind B, von Gegerfelt A, Albert J, Olausson E, Asjo B: Distinct replicative and cytopathic characteristics of human immunodeficiency virus isolates. J Virol. 1988, 62: 4414-4419.PubMedCentralPubMed

39.

Schuitemaker H, Kootstra NA, de Goede RE, de Wolf F, Miedema F, Tersmette M: Monocytotropic human immunodeficiency virus type 1 (HIV-1) variants detectable in all stages of HIV-1 infection lack T-cell line tropism and syncytium-inducing ability in primary T-cell culture. J Virol. 1991, 65: 356-363.PubMedCentralPubMed

40.

Tersmette M, Gruters RA, de Wolf F, de Goede RE, Lange JM, Schellekens PT, Goudsmit J, Huisman HG, Miedema F: Evidence for a role of virulent human immunodeficiency virus (HIV) variants in the pathogenesis of acquired immunodeficiency syndrome: studies on sequential HIV isolates. J Virol. 1989, 63: 2118-2125.PubMedCentralPubMed

41.

Gruters RA, Terpstra FG, De Goede RE, Mulder JW, De Wolf F, Schellekens PT, Van Lier RA, Tersmette M, Miedema F: Immunological and virological markers in individuals progressing from seroconversion to AIDS. Aids. 1991, 5: 837-844. 10.1097/00002030-199107000-00007.PubMed

42.

Koot M, Keet IP, Vos AH, de Goede RE, Roos MT, Coutinho RA, Miedema F, Schellekens PT, Tersmette M: Prognostic value of HIV-1 syncytium-inducing phenotype for rate of CD4+ cell depletion and progression to AIDS. Ann Intern Med. 1993, 118: 681-688.PubMed

43.

Gendelman HE, Orenstein JM, Martin MA, Ferrua C, Mitra R, Phipps T, Wahl LA, Lane HC, Fauci AS, Burke DS: Efficient isolation and propagation of human immunodeficiency virus on recombinant colony-stimulating factor 1-treated monocytes. J Exp Med. 1988, 167: 1428-1441. 10.1084/jem.167.4.1428.PubMed

44.

Schwartz S, Felber BK, Fenyo EM, Pavlakis GN: Rapidly and slowly replicating human immunodeficiency virus type 1 isolates can be distinguished according to target-cell tropism in T-cell and monocyte cell lines. Proc Natl Acad Sci U S A. 1989, 86: 7200-7203. 10.1073/pnas.86.18.7200.PubMedCentralPubMed

45.

Fenyo EM, Albert J, Asjo B: Replicative capacity, cytopathic effect and cell tropism of HIV. AIDS. 1989, 3 (Suppl 1): S5-12. 10.1097/00002030-198901001-00002.PubMed

46.

Valentin A, Albert J, Fenyo EM, Asjo B: HIV-1 infection of normal human macrophage cultures: implication for silent infection. Virology. 1990, 177: 790-794. 10.1016/0042-6822(90)90551-2.PubMed

47.

Valentin A, Albert J, Fenyo EM, Asjo B: Dual tropism for macrophages and lymphocytes is a common feature of primary human immunodeficiency virus type 1 and 2 isolates. J Virol. 1994, 68: 6684-6689.PubMedCentralPubMed

48.

Harada S, Koyanagi Y, Yamamoto N: Infection of HTLV-III/LAV in HTLV-I-carrying cells MT-2 and MT-4 and application in a plaque assay. Science. 1985, 229: 563-566. 10.1126/science.2992081.PubMed

49.

Koot M, Vos AH, Keet RP, de Goede RE, Dercksen MW, Terpstra FG, Coutinho RA, Miedema F, Tersmette M: HIV-1 biological phenotype in long-term infected individuals evaluated with an MT-2 cocultivation assay. Aids. 1992, 6: 49-54. 10.1097/00002030-199201000-00006.PubMed

50.

Schuitemaker H, Koot M, Kootstra NA, Dercksen MW, de Goede RE, van Steenwijk RP, Lange JM, Schattenkerk JK, Miedema F, Tersmette M: Biological phenotype of human immunodeficiency virus type 1 clones at different stages of infection: progression of disease is associated with a shift from monocytotropic to T-cell-tropic virus population. J Virol. 1992, 66: 1354-1360.PubMedCentralPubMed

51.

Karlsson A, Parsmyr K, Sandstrom E, Fenyo EM, Albert J: MT-2 cell tropism as prognostic marker for disease progression in human immunodeficiency virus type 1 infection. J Clin Microbiol. 1994, 32: 364-370.PubMedCentralPubMed

52.

Schneider T, Jahn HU, Schmidt W, Riecken EO, Zeitz M, Ullrich R: Loss of CD4 T lymphocytes in patients infected with human immunodeficiency virus type 1 is more pronounced in the duodenal mucosa than in the peripheral blood. Berlin Diarrhea/Wasting Syndrome Study Group. Gut. 1995, 37: 524-529. 10.1136/gut.37.4.524.PubMedCentralPubMed

53.

Bishop PE, McMillan A, Gilmour HM: Immunological study of the rectal mucosa of men with and without human immunodeficiency virus infection. Gut. 1987, 28: 1619-1624. 10.1136/gut.28.12.1619.PubMedCentralPubMed

54.

Collman R, Godfrey B, Cutilli J, Rhodes A, Hassan NF, Sweet R, Douglas SD, Friedman H, Nathanson N, Gonzalez-Scarano F: Macrophage-tropic strains of human immunodeficiency virus type 1 utilize the CD4 receptor. J Virol. 1990, 64: 4468-4476.PubMedCentralPubMed

55.

Cordonnier A, Montagnier L, Emerman M: Single amino-acid changes in HIV envelope affect viral tropism and receptor binding. Nature. 1989, 340: 571-574. 10.1038/340571a0.PubMed

56.

O'Brien WA, Koyanagi Y, Namazie A, Zhao JQ, Diagne A, Idler K, Zack JA, Chen IS: HIV-1 tropism for mononuclear phagocytes can be determined by regions of gp120 outside the CD4-binding domain. Nature. 1990, 348: 69-73. 10.1038/348069a0.PubMed

57.

Schuitemaker H, Groenink M, Tersmette M, Miedema F: HIV tropism. Nature. 1993, 361: 310-10.1038/361310a0.PubMed

58.

Weiner DB, Huebner K, Williams WV, Greene MI: Human genes other than CD4 facilitate HIV-1 infection of murine cells. Pathobiology. 1991, 59: 361-371. 10.1159/000163679.PubMed

59.

Alkhatib G, Broder CC, Berger EA: Cell type-specific fusion cofactors determine human immunodeficiency virus type 1 tropism for T-cell lines versus primary macrophages. J Virol. 1996, 70: 5487-5494.PubMedCentralPubMed

60.

Harrington RD, Geballe AP: Cofactor requirement for human immunodeficiency virus type 1 entry into a CD4-expressing human cell line. J Virol. 1993, 67: 5939-5947.PubMedCentralPubMed

61.

Feng Y, Broder CC, Kennedy PE, Berger EA: HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science. 1996, 272: 872-877. 10.1126/science.272.5263.872.PubMed

62.

Bleul CC, Farzan M, Choe H, Parolin C, Clark-Lewis I, Sodroski J, Springer TA: The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry. Nature. 1996, 382: 829-833. 10.1038/382829a0.PubMed

63.

Oberlin E, Amara A, Bachelerie F, Bessia C, Virelizier JL, Arenzana-Seisdedos F, Schwartz O, Heard JM, Clark-Lewis I, Legler DF: The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T-cell-line-adapted HIV-1. Nature. 1996, 382: 833-835. 10.1038/382833a0.PubMed

64.

Cocchi F, DeVico AL, Garzino-Demo A, Arya SK, Gallo RC, Lusso P: Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV- suppressive factors produced by CD8+ T cells. Science. 1995, 270: 1811-1815. 10.1126/science.270.5243.1811.PubMed

65.

Combadiere C, Ahuja SK, Tiffany HL, Murphy PM: Cloning and functional expression of CC CKR5, a human monocyte CC chemokine receptor selective for MIP-1(alpha), MIP-1(beta), and RANTES. J Leukoc Biol. 1996, 60: 147-152.PubMed

66.

Raport CJ, Gosling J, Schweickart VL, Gray PW, Charo IF: Molecular cloning and functional characterization of a novel human CC chemokine receptor (CCR5) for RANTES, MIP-1beta, and MIP-1alpha. J Biol Chem. 1996, 271: 17161-17166. 10.1074/jbc.271.29.17161.PubMed

67.

Samson M, Labbe O, Mollereau C, Vassart G, Parmentier M: Molecular cloning and functional expression of a new human CC-chemokine receptor gene. Biochemistry. 1996, 35: 3362-3367. 10.1021/bi952950g.PubMed

68.

Choe H, Farzan M, Sun Y, Sullivan N, Rollins B, Ponath PD, Wu L, Mackay CR, LaRosa G, Newman W: The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell. 1996, 85: 1135-1148. 10.1016/S0092-8674(00)81313-6.PubMed

69.

Bjorndal A, Deng H, Jansson M, Fiore JR, Colognesi C, Karlsson A, Albert J, Scarlatti G, Littman DR, Fenyo EM: Coreceptor usage of primary human immunodeficiency virus type 1 isolates varies according to biological phenotype. J Virol. 1997, 71: 7478-7487.PubMedCentralPubMed

70.

Cheng-Mayer C, Liu R, Landau NR, Stamatatos L: Macrophage tropism of human immunodeficiency virus type 1 and utilization of the CC-CKR5 coreceptor. J Virol. 1997, 71: 1657-1661.PubMedCentralPubMed

71.

Simmons G, Wilkinson D, Reeves JD, Dittmar MT, Beddows S, Weber J, Carnegie G, Desselberger U, Gray PW, Weiss RA, Clapham PR: Primary, syncytium-inducing human immunodeficiency virus type 1 isolates are dual-tropic and most can use either Lestr or CCR5 as coreceptors for virus entry. J Virol. 1996, 70: 8355-8360.PubMedCentralPubMed

72.

Berger EA, Murphy PM, Farber JM: Chemokine receptors as HIV-1 coreceptors: Roles in viral entry, tropism and disease. Ann Rev Immunol. 1999, 17: 657-700. 10.1146/annurev.immunol.17.1.657.

73.

Lee S, Tiffany HL, King L, Murphy PM, Golding H, Zaitseva MB: CCR8 on human thymocytes functions as a human immunodeficiency virus type 1 coreceptor. J Virol. 2000, 74: 6946-6952. 10.1128/JVI.74.15.6946-6952.2000.PubMedCentralPubMed

74.

Sharron M, Pohlmann S, Price K, Lolis E, Tsang M, Kirchhoff F, Doms RW, Lee B: Expression and coreceptor activity of STRL33/Bonzo on primary peripheral blood lymphocytes. Blood. 2000, 96: 41-49.PubMed

75.

O'Brien TR, Winkler C, Dean M, Nelson JA, Carrington M, Michael NL, White GC: HIV-1 infection in a man homozygous for CCR5 delta 32. Lancet. 1997, 349: 1219-10.1016/S0140-6736(97)24017-1.PubMed

76.

Samson M, Libert F, Doranz BJ, Rucker J, Liesnard C, Farber CM, Saragosti S, Lapoumeroulie C, Cognaux J, Forceille C: Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature. 1996, 382: 722-725. 10.1038/382722a0.PubMed

77.

Gorry PR, Zhang C, Wu S, Kunstman K, Trachtenberg E, Phair J, Wolinsky S, Gabuzda D: Persistence of dual-tropic HIV-1 in an individual homozygous for the CCR5 Delta 32 allele. Lancet. 2002, 359: 1832-1834. 10.1016/S0140-6736(02)08681-6.PubMed

78.

Michael NL, Nelson JA, KewalRamani VN, Chang G, O'Brien SJ, Mascola JR, Volsky B, Louder M, White GC, Littman DR: Exclusive and persistent use of the entry coreceptor CXCR4 by human immunodeficiency virus type 1 from a subject homozygous for CCR5 delta32. Journal of virology. 1998, 72: 6040-6047.PubMedCentralPubMed

79.

Rowe PM: CKR-5 deletion heterozygotes progress slower to AIDS. Lancet. 1996, 348: 947-10.1016/S0140-6736(05)65339-1.PubMed

80.

Karlsson I, Grivel JC, Chen SS, Karlsson A, Albert J, Fenyo EM, Margolis LB: Differential pathogenesis of primary CCR5-using human immunodeficiency virus type 1 isolates in ex vivo human lymphoid tissue. Journal of virology. 2005, 79: 11151-11160. 10.1128/JVI.79.17.11151-11160.2005.PubMedCentralPubMed

81.

Goodenow MM, Collman RG: HIV-1 coreceptor preference is distinct from target cell tropism: a dual-parameter nomenclature to define viral phenotypes. J Leukoc Biol. 2006, 80: 965-972. 10.1189/jlb.0306148.PubMed

82.

Glushakova S, Yi Y, Grivel JC, Singh A, Schols D, De Clercq E, Collman RG, Margolis L: Preferential coreceptor utilization and cytopathicity by dual-tropic HIV-1 in human lymphoid tissue ex vivo. J Clin Invest. 1999, 104: R7-R11. 10.1172/JCI7403.PubMedCentralPubMed

83.

Bleul CC, Wu L, Hoxie JA, Springer TA, Mackay CR: The HIV coreceptors CXCR4 and CCR5 are differentially expressed and regulated on human T lymphocytes. Proc Natl Acad Sci U S A. 1997, 94: 1925-1930. 10.1073/pnas.94.5.1925.PubMedCentralPubMed

84.

Gondois-Rey F, Grivel JC, Biancotto A, Pion M, Vigne R, Margolis LB, Hirsch I: Segregation of R5 and X4 HIV-1 variants to memory T cell subsets differentially expressing CD62L in ex vivo infected human lymphoid tissue. Aids. 2002, 16: 1245-1249. 10.1097/00002030-200206140-00006.PubMed

85.

Grivel J-C, Margolis LB: CCR5- and CXCR4-tropic HIV-1 are equally cytopathic for their T-cell targets in human lymphoid tissue. Nature Medicine. 1999, 5: 344-346. 10.1038/6565.PubMed

86.

Brenchley JM, Schacker TW, Ruff LE, Price DA, Taylor JH, Beilman GJ, Nguyen PL, Khoruts A, Larson M, Haase AT, Douek DC: CD4+ T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract. J Exp Med. 2004, 200: 749-759. 10.1084/jem.20040874.PubMedCentralPubMed

87.

Guadalupe M, Reay E, Sankaran S, Prindiville T, Flamm J, McNeil A, Dandekar S: Severe CD4+ T-cell depletion in gut lymphoid tissue during primary human immunodeficiency virus type 1 infection and substantial delay in restoration following highly active antiretroviral therapy. Journal of virology. 2003, 77: 11708-11717. 10.1128/JVI.77.21.11708-11717.2003.PubMedCentralPubMed

88.

Lim SG, Condez A, Lee CA, Johnson MA, Elia C, Poulter LW: Loss of mucosal CD4 lymphocytes is an early feature of HIV infection. Clin Exp Immunol. 1993, 92: 448-454. 10.1111/j.1365-2249.1993.tb03419.x.PubMedCentralPubMed

89.

Ullrich R, Zeitz M, Heise W, L'Age M, Ziegler K, Bergs C, Riecken EO: Mucosal atrophy is associated with loss of activated T cells in the duodenal mucosa of human immunodeficiency virus (HIV)-infected patients. Digestion. 1990, 46 (Suppl 2): 302-307. 10.1159/000200401.PubMed

90.

Grivel JC, Elliott J, Lisco A, Biancotto A, Condack C, Shattock RJ, McGowan I, Margolis L, Anton P: HIV-1 pathogenesis differs in rectosigmoid and tonsillar tissues infected ex vivo with CCR5- and CXCR4-tropic HIV-1. Aids. 2007, 21: 1263-1272. 10.1097/QAD.0b013e3281864667.PubMed

91.

Haaland RE, Hawkins PA, Salazar-Gonzalez J, Johnson A, Tichacek A, Karita E, Manigart O, Mulenga J, Keele BF, Shaw GM: Inflammatory genital infections mitigate a severe genetic bottleneck in heterosexual transmission of subtype A and C HIV-1. PLoS Pathog. 2009, 5: e1000274-10.1371/journal.ppat.1000274.PubMedCentralPubMed

92.

O'Connor DM: A tissue basis for colposcopic findings. Obstet Gynecol Clin North Am. 2008, 35: 565-582. 10.1016/j.ogc.2008.09.009. viiiPubMed

93.

Pudney J, Quayle AJ, Anderson DJ: Immunological Microenvironments in the Human Vagina and Cervix: Mediators of Cellular Immunity Are Concentrated in the Cervical Transformation Zone. Biol Reprod. 2005

94.

Haase AT: Targeting early infection to prevent HIV-1 mucosal transmission. Nature. 2010, 464: 217-223. 10.1038/nature08757.PubMed

95.

Miller CJ, Shattock RJ: Target cells in vaginal HIV transmission. Microbes Infect. 2003, 5: 59-67. 10.1016/S1286-4579(02)00056-4.PubMed

96.

Kell PD, Barton SE, Edmonds DK, Boag FC: HIV infection in a patient with Meyer-Rokitansky-Kuster-Hauser syndrome. J R Soc Med. 1992, 85: 706-707.PubMedCentralPubMed

97.

Miller CJ, Alexander NJ, Vogel P, Anderson J, Marx PA: Mechanism of genital transmission of SIV: a hypothesis based on transmission studies and the location of SIV in the genital tract of chronically infected female rhesus macaques. J Med Primatol. 1992, 21: 64-68.PubMed

98.

Anderson DJ, Politch JA, Nadolski AM, Blaskewicz CD, Pudney J, Mayer KH: Targeting Trojan Horse leukocytes for HIV prevention. AIDS. 2010, 24: 163-187. 10.1097/QAD.0b013e32833424c8.PubMedCentralPubMed

99.

Argueso P, Spurr-Michaud S, Tisdale A, Gipson IK: Variation in the amount of T antigen and N-acetyllactosamine oligosaccharides in human cervical mucus secretions with the menstrual cycle. J Clin Endocrinol Metab. 2002, 87: 5641-5648. 10.1210/jc.2002-020766.PubMed

100.

Olmsted SS, Padgett JL, Yudin AI, Whaley KJ, Moench TR, Cone RA: Diffusion of macromolecules and virus-like particles in human cervical mucus. Biophys J. 2001, 81: 1930-1937. 10.1016/S0006-3495(01)75844-4.PubMedCentralPubMed

101.

Lai SK, Hida K, Shukair S, Wang YY, Figueiredo A, Cone R, Hope TJ, Hanes J: Human immunodeficiency virus type 1 is trapped by acidic but not by neutralized human cervicovaginal mucus. Journal of virology. 2009, 83: 11196-11200. 10.1128/JVI.01899-08.PubMedCentralPubMed

102.

Lai SK, O'Hanlon DE, Harrold S, Man ST, Wang YY, Cone R, Hanes J: Rapid transport of large polymeric nanoparticles in fresh undiluted human mucus. Proc Natl Acad Sci U S A. 2007, 104: 1482-1487. 10.1073/pnas.0608611104.PubMedCentralPubMed

103.

Boukari H, Brichacek B, Stratton P, Mahoney SF, Lifson JD, Margolis L, Nossal R: Movements of HIV-virions in human cervical mucus. Biomacromolecules. 2009, 10: 2482-2488. 10.1021/bm900344q.PubMedCentralPubMed

104.

Agace WW, Amara A, Roberts AI, Pablos JL, Thelen S, Uguccioni M, Li XY, Marsal J, Arenzana-Seisdedos F, Delaunay T: Constitutive expression of stromal derived factor-1 by mucosal epithelia and its role in HIV transmission and propagation. Curr Biol. 2000, 10: 325-328. 10.1016/S0960-9822(00)00380-8.PubMed

105.

Bomsel M, David V: Mucosal gatekeepers: selecting HIV viruses for early infection. Nat Med. 2002, 8: 114-116. 10.1038/nm0202-114.PubMed

106.

Furci L, Sironi F, Tolazzi M, Vassena L, Lusso P: Alpha-defensins block the early steps of HIV-1 infection: interference with the binding of gp120 to CD4. Blood. 2007, 109: 2928-2935.PubMed

107.

Wira CR, Grant-Tschudy KS, Crane-Godreau MA: Epithelial cells in the female reproductive tract: a central role as sentinels of immune protection. Am J Reprod Immunol. 2005, 53: 65-76. 10.1111/j.1600-0897.2004.00248.x.PubMed

108.

Wira CR, Fahey JV, Sentman CL, Pioli PA, Shen L: Innate and adaptive immunity in female genital tract: cellular responses and interactions. Immunol Rev. 2005, 206: 306-335. 10.1111/j.0105-2896.2005.00287.x.PubMed

109.

Seidel A, Ye Y, de Armas LR, Soto M, Yarosh W, Marcsisin RA, Tran D, Selsted ME, Camerini D: Cyclic and acyclic defensins inhibit human immunodeficiency virus type-1 replication by different mechanisms. PLoS One. 2010, 5: e9737-10.1371/journal.pone.0009737.PubMedCentralPubMed

110.

Sun L, Finnegan CM, Kish-Catalone T, Blumenthal R, Garzino-Demo P, La Terra Maggiore GM, Berrone S, Kleinman C, Wu Z, Abdelwahab S: Human beta-defensins suppress human immunodeficiency virus infection: potential role in mucosal protection. Journal of virology. 2005, 79: 14318-14329. 10.1128/JVI.79.22.14318-14329.2005.PubMedCentralPubMed

111.

Feng Z, Dubyak GR, Lederman MM, Weinberg A: Cutting edge: human beta defensin 3--a novel antagonist of the HIV-1 coreceptor CXCR4. J Immunol. 2006, 177: 782-786.PubMed

112.

Quinones-Mateu ME, Lederman MM, Feng Z, Chakraborty B, Weber J, Rangel HR, Marotta ML, Mirza M, Jiang B, Kiser P: Human epithelial beta-defensins 2 and 3 inhibit HIV-1 replication. AIDS. 2003, 17: F39-48. 10.1097/00002030-200311070-00001.PubMed

113.

Zegels G, Van Raemdonck GA, Coen EP, Tjalma WA, Van Ostade XW: Comprehensive proteomic analysis of human cervical-vaginal fluid using colposcopy samples. Proteome Sci. 2009, 7: 17-10.1186/1477-5956-7-17.PubMedCentralPubMed

114.

Habte HH, de Beer C, Lotz ZE, Tyler MG, Schoeman L, Kahn D, Mall AS: The inhibition of the Human Immunodeficiency Virus type 1 activity by crude and purified human pregnancy plug mucus and mucins in an inhibition assay. Virol J. 2008, 5: 59-10.1186/1743-422X-5-59.PubMedCentralPubMed

115.

Kwong PD, Wyatt R, Sattentau QJ, Sodroski J, Hendrickson WA: Oligomeric modeling and electrostatic analysis of the gp120 envelope glycoprotein of human immunodeficiency virus. J Virol. 2000, 74: 1961-1972. 10.1128/JVI.74.4.1961-1972.2000.PubMedCentralPubMed

116.

Moulard M, Lortat-Jacob H, Mondor I, Roca G, Wyatt R, Sodroski J, Zhao L, Olson W, Kwong PD, Sattentau QJ: Selective interactions of polyanions with basic surfaces on human immunodeficiency virus type 1 gp120. J Virol. 2000, 74: 1948-1960. 10.1128/JVI.74.4.1948-1960.2000.PubMedCentralPubMed

117.

Vives RR, Imberty A, Sattentau QJ, Lortat-Jacob H: Heparan sulfate targets the HIV-1 envelope glycoprotein gp120 coreceptor binding site. J Biol Chem. 2005, 280: 21353-21357. 10.1074/jbc.M500911200.PubMed

118.

Alfsen A, Yu H, Magerus-Chatinet A, Schmitt A, Bomsel M: HIV-1-infected blood mononuclear cells form an integrin- and agrin-dependent viral synapse to induce efficient HIV-1 transcytosis across epithelial cell monolayer. Mol Biol Cell. 2005, 16: 4267-4279. 10.1091/mbc.E05-03-0192.PubMedCentralPubMed

119.

Wira CR, Fahey JV: A new strategy to understand how HIV infects women: identification of a window of vulnerability during the menstrual cycle. AIDS. 2008, 22: 1909-1917. 10.1097/QAD.0b013e3283060ea4.PubMedCentralPubMed

120.

Yeaman GR, Howell AL, Weldon S, Demian DJ, Collins JE, O'Connell DM, Asin SN, Wira CR, Fanger MW: Human immunodeficiency virus receptor and coreceptor expression on human uterine epithelial cells: regulation of expression during the menstrual cycle and implications for human immunodeficiency virus infection. Immunology. 2003, 109: 137-146. 10.1046/j.1365-2567.2003.01623.x.PubMedCentralPubMed

121.

Heise C, Miller CJ, Lackner A, Dandekar S: Primary acute simian immunodeficiency virus infection of intestinal lymphoid tissue is associated with gastrointestinal dysfunction. J Infect Dis. 1994, 169: 1116-1120.PubMed

122.

Phillips DM, Zacharopoulos VR, Tan X, Pearce-Pratt R: Mechanisms of sexual transmission of HIV: does HIV infect intact epithelia?. Trends Microbiol. 1994, 2: 454-458. 10.1016/0966-842X(94)90804-4.PubMed

123.

Norvell MK, Benrubi GI, Thompson RJ: Investigation of microtrauma after sexual intercourse. J Reprod Med. 1984, 29: 269-271.PubMed

124.

Ganor Y, Zhou Z, Tudor D, Schmitt A, Vacher-Lavenu MC, Gibault L, Thiounn N, Tomasini J, Wolf JP, Bomsel M: Within 1 h, HIV-1 uses viral synapses to enter efficiently the inner, but not outer, foreskin mucosa and engages Langerhans-T cell conjugates. Mucosal Immunol. 2010

125.

Platt EJ, Kozak SL, Durnin JP, Hope TJ, Kabat D: Rapid dissociation of HIV-1 from cultured cells severely limits infectivity assays, causes the inactivation ascribed to entry inhibitors, and masks the inherently high level of infectivity of virions. J Virol. 2010, 84: 3106-3110. 10.1128/JVI.01958-09.PubMedCentralPubMed

126.

Zhang Z, Schuler T, Zupancic M, Wietgrefe S, Staskus KA, Reimann KA, Reinhart TA, Rogan M, Cavert W, Miller CJ: Sexual transmission and propagation of SIV and HIV in resting and activated CD4+ T cells. Science. 1999, 286: 1353-1357. 10.1126/science.286.5443.1353.PubMed

127.

Grivel JC, Margolis L: Use of human tissue explants to study human infectious agents. Nat Protoc. 2009, 4: 256-269. 10.1038/nprot.2008.245.PubMedCentralPubMed

128.

Saba E, Grivel JC, Vanpouille C, Brichacek B, Fitzgerald W, Margolis L, Lisco A: HIV-1 sexual transmission: early events of HIV-1 infection of human cervico-vaginal tissue in an optimized ex vivo model. Mucosal Immunol. 2010, 3: 280-290. 10.1038/mi.2010.2.PubMedCentralPubMed

129.

Yeaman GR, Asin S, Weldon S, Demian DJ, Collins JE, Gonzalez JL, Wira CR, Fanger MW, Howell AL: Chemokine receptor expression in the human ectocervix: implications for infection by the human immunodeficiency virus-type I. Immunology. 2004, 113: 524-533. 10.1111/j.1365-2567.2004.01990.x.PubMedCentralPubMed

130.

Patterson BK, Landay A, Andersson J, Brown C, Behbahani H, Jiyamapa D, Burki Z, Stanislawski D, Czerniewski MA, Garcia P: Repertoire of chemokine receptor expression in the female genital tract: implications for human immunodeficiency virus transmission. Am J Pathol. 1998, 153: 481-490.PubMedCentralPubMed

131.

McClure CP, Tighe PJ, Robins RA, Bansal D, Bowman CA, Kingston M, Ball JK: HIV coreceptor and chemokine ligand gene expression in the male urethra and female cervix. Aids. 2005, 19: 1257-1265. 10.1097/01.aids.0000180096.50393.96.PubMed

132.

Hladik F, Sakchalathorn P, Ballweber L, Lentz G, Fialkow M, Eschenbach D, McElrath MJ: Initial events in establishing vaginal entry and infection by human immunodeficiency virus type-1. Immunity. 2007, 26: 257-270. 10.1016/j.immuni.2007.01.007.PubMedCentralPubMed

133.

Hussain LA, Lehner T: Comparative investigation of Langerhans' cells and potential receptors for HIV in oral, genitourinary and rectal epithelia. Immunology. 1995, 85: 475-484.PubMedCentralPubMed

134.

Turville SG, Cameron PU, Handley A, Lin G, Pohlmann S, Doms RW, Cunningham AL: Diversity of receptors binding HIV on dendritic cell subsets. Nat Immunol. 2002, 3: 975-983. 10.1038/ni841.PubMed

135.

Zacharopoulos VR, Perotti ME, Phillips DM: A role for cell migration in the sexual transmission of HIV-1?. Curr Biol. 1997, 7: 534-537. 10.1016/S0960-9822(06)00225-9.PubMed

136.

Hladik F, McElrath MJ: Setting the stage: host invasion by HIV. Nat Rev Immunol. 2008, 8: 447-457. 10.1038/nri2302.PubMedCentralPubMed

137.

Spira AI, Marx PA, Patterson BK, Mahoney J, Koup RA, Wolinsky SM, Ho DD: Cellular targets of infection and route of viral dissemination after an intravaginal inoculation of simian immunodeficiency virus into rhesus macaques. J Exp Med. 1996, 183: 215-225. 10.1084/jem.183.1.215.PubMed

138.

Jayakumar P, Berger I, Autschbach F, Weinstein M, Funke B, Verdin E, Goldsmith MA, Keppler OT: Tissue-resident macrophages are productively infected ex vivo by primary X4 isolates of human immunodeficiency virus type 1. Journal of virology. 2005, 79: 5220-5226. 10.1128/JVI.79.8.5220-5226.2005.PubMedCentralPubMed

139.

McCoombe SG, Short RV: Potential HIV-1 target cells in the human penis. AIDS. 2006, 20: 1491-1495. 10.1097/01.aids.0000237364.11123.98.PubMed

140.

Dinh MH, McRaven MD, Kelley Z, Penugonda S, Hope TJ: Keratinization of the adult male foreskin and implications for male circumcision. Aids. 2010, 24: 899-906. 10.1097/QAD.0b013e3283367779.PubMedCentralPubMed

141.

Patterson BK, Landay A, Siegel JN, Flener Z, Pessis D, Chaviano A, Bailey RC: Susceptibility to human immunodeficiency virus-1 infection of human foreskin and cervical tissue grown in explant culture. Am J Pathol. 2002, 161: 867-873.PubMedCentralPubMed

142.

Donoval BA, Landay AL, Moses S, Agot K, Ndinya-Achola JO, Nyagaya EA, MacLean I, Bailey RC: HIV-1 target cells in foreskins of African men with varying histories of sexually transmitted infections. Am J Clin Pathol. 2006, 125: 386-391.PubMed

143.

McClure CP, Tighe PJ, Robins RA, Bansal D, Bowman CA, Kingston M, Ball JK: HIV coreceptor and chemokine ligand gene expression in the male urethra and female cervix. AIDS. 2005, 19: 1257-1265. 10.1097/01.aids.0000180096.50393.96.PubMed

144.

Chenine AL, Siddappa NB, Kramer VG, Sciaranghella G, Rasmussen RA, Lee SJ, Santosuosso M, Poznansky MC, Velu V, Amara RR: Relative transmissibility of an R5 clade C simian-human immunodeficiency virus across different mucosae in macaques parallels the relative risks of sexual HIV-1 transmission in humans via different routes. J Infect Dis. 2010, 201: 1155-1163. 10.1086/651274.PubMedCentralPubMed

145.

Nazli A, Chan O, Dobson-Belaire WN, Ouellet M, Tremblay MJ, Gray-Owen SD, Arsenault AL, Kaushic C: Exposure to HIV-1 directly impairs mucosal epithelial barrier integrity allowing microbial translocation. PLoS Pathog. 2010, 6: e1000852-10.1371/journal.ppat.1000852.PubMedCentralPubMed

146.

Olsson J, Poles M, Spetz AL, Elliott J, Hultin L, Giorgi J, Andersson J, Anton P: Human immunodeficiency virus type 1 infection is associated with significant mucosal inflammation characterized by increased expression of CCR5, CXCR4, and beta-chemokines. J Infect Dis. 2000, 182: 1625-1635. 10.1086/317625.PubMed

147.

Poles MA, Elliott J, Taing P, Anton PA, Chen IS: A preponderance of CCR5(+) CXCR4(+) mononuclear cells enhances gastrointestinal mucosal susceptibility to human immunodeficiency virus type 1 infection. J Virol. 2001, 75: 8390-8399. 10.1128/JVI.75.18.8390-8399.2001.PubMedCentralPubMed

148.

Brenchley JM, Price DA, Douek DC: HIV disease: fallout from a mucosal catastrophe?. Nat Immunol. 2006, 7: 235-239. 10.1038/ni1316.PubMed

149.

Bomsel M: Transcytosis of infectious human immunodeficiency virus across a tight human epithelial cell line barrier. Nat Med. 1997, 3: 42-47. 10.1038/nm0197-42.PubMed

150.

Shen R, Smythies LE, Clements RH, Novak L, Smith PD: Dendritic cells transmit HIV-1 through human small intestinal mucosa. J Leukoc Biol. 2010, 87: 663-670. 10.1189/jlb.0909605.PubMedCentralPubMed

151.

Wolinsky SM, Wike CM, Korber BT, Hutto C, Parks WP, Rosenblum LL, Kunstman KJ, Furtado MR, Munoz JL: Selective transmission of human immunodeficiency virus type-1 variants from mothers to infants. Science. 1992, 255: 1134-1137. 10.1126/science.1546316.PubMed

152.

153.

van't Wout AB, Kootstra NA, Mulder-Kampinga GA, Albrecht-van Lent N, Scherpbier HJ, Veenstra J, Boer K, Coutinho RA, Miedema F, Schuitemaker H: Macrophage-tropic variants initiate human immunodeficiency virus type 1 infection after sexual, parenteral, and vertical transmission. J Clin Invest. 1994, 94: 2060-2067. 10.1172/JCI117560.PubMedCentralPubMed

154.

Scarlatti G, Tresoldi E, Bjorndal A, Fredriksson R, Colognesi C, Deng HK, Malnati MS, Plebani A, Siccardi AG, Littman DR: In vivo evolution of HIV-1 co-receptor usage and sensitivity to chemokine-mediated suppression. Nat Med. 1997, 3: 1259-1265. 10.1038/nm1197-1259.PubMed

155.

Matala E, Hahn T, Yedavalli VR, Ahmad N: Biological characterization of HIV type 1 envelope V3 regions from mothers and infants associated with perinatal transmission. AIDS Res Hum Retroviruses. 2001, 17: 1725-1735. 10.1089/08892220152741423.PubMed

156.

Fultz PN: Components of saliva inactivate human immunodeficiency virus. Lancet. 1986, 2: 1215-10.1016/S0140-6736(86)92218-X.PubMed

157.

Malamud D, Davis C, Berthold P, Roth E, Friedman H: Human submandibular saliva aggregates HIV. AIDS Res Hum Retroviruses. 1993, 9: 633-637. 10.1089/aid.1993.9.633.PubMed

158.

Nagashunmugam T, Friedman HM, Davis C, Kennedy S, Goldstein LT, Malamud D: Human submandibular saliva specifically inhibits HIV type 1. AIDS Res Hum Retroviruses. 1997, 13: 371-376. 10.1089/aid.1997.13.371.PubMed

159.

McNeely TB, Dealy M, Dripps DJ, Orenstein JM, Eisenberg SP, Wahl SM: Secretory leukocyte protease inhibitor: a human saliva protein exhibiting anti-human immunodeficiency virus 1 activity in vitro. J Clin Invest. 1995, 96: 456-464. 10.1172/JCI118056.PubMedCentralPubMed

160.

Weinberg A, Quinones-Mateu ME, Lederman MM: Role of human beta-defensins in HIV infection. Adv Dent Res. 2006, 19: 42-48. 10.1177/154407370601900109.PubMed

161.

Abel K, Pahar B, Van Rompay KK, Fritts L, Sin C, Schmidt K, Colon R, McChesney M, Marthas ML: Rapid virus dissemination in infant macaques after oral simian immunodeficiency virus exposure in the presence of local innate immune responses. Journal of virology. 2006, 80: 6357-6367. 10.1128/JVI.02240-05.PubMedCentralPubMed

162.

Meng G, Wei X, Wu X, Sellers MT, Decker JM, Moldoveanu Z, Orenstein JM, Graham MF, Kappes JC, Mestecky J: Primary intestinal epithelial cells selectively transfer R5 HIV-1 to CCR5+ cells. Nat Med. 2002, 8: 150-156. 10.1038/nm0202-150.PubMed

163.

Salvatori F, Scarlatti G: HIV type 1 chemokine receptor usage in mother-to-child transmission. AIDS Res Hum Retroviruses. 2001, 17: 925-935. 10.1089/088922201750290041.PubMed

164.

Clevestig P, Maljkovic I, Casper C, Carlenor E, Lindgren S, Naver L, Bohlin AB, Fenyo EM, Leitner T, Ehrnst A: The X4 phenotype of HIV type 1 evolves from R5 in two children of mothers, carrying X4, and is not linked to transmission. AIDS Res Hum Retroviruses. 2005, 21: 371-378. 10.1089/aid.2005.21.371.PubMed

165.

Huang W, Eshleman SH, Toma J, Stawiski E, Whitcomb JM, Jackson JB, Guay L, Musoke P, Parkin N, Petropoulos CJ: Vertical transmission of X4-tropic and dual-tropic HIV-1 in five Ugandan mother-infant pairs. AIDS. 2009, 23: 1903-1908. 10.1097/QAD.0b013e32832f1802.PubMedCentralPubMed

166.

Fenyo EM: Viral phenotype and severity of HIV-1 infection: are children different from adults?. Aids. 1993, 7: 1673-1674. 10.1097/00002030-199312000-00020.PubMed

167.

Spijkerman IJ, Koot M, Prins M, Keet IP, van den Hoek AJ, Miedema F, Coutinho RA: Lower prevalence and incidence of HIV-1 syncytium-inducing phenotype among injecting drug users compared with homosexual men. AIDS. 1995, 9: 1085-1092. 10.1097/00002030-199509000-00016.PubMed

168.

Schutten M, van Baalen CA, Guillon C, Huisman RC, Boers PH, Sintnicolaas K, Gruters RA, Osterhaus AD: Macrophage tropism of human immunodeficiency virus type 1 facilitates in vivo escape from cytotoxic T-lymphocyte pressure. J Virol. 2001, 75: 2706-2709. 10.1128/JVI.75.6.2706-2709.2001.PubMedCentralPubMed

169.

Harouse JM, Buckner C, Gettie A, Fuller R, Bohm R, Blanchard J, Cheng-Mayer C: CD8+ T cell-mediated CXC chemokine receptor 4-simian/human immunodeficiency virus suppression in dually infected rhesus macaques. Proc Natl Acad Sci U S A. 2003, 100: 10977-10982. 10.1073/pnas.1933268100.PubMedCentralPubMed

170.

David SA, Smith MS, Lopez GJ, Adany I, Mukherjee S, Buch S, Goodenow MM, Narayan O: Selective transmission of R5-tropic HIV type 1 from dendritic cells to resting CD4+ T cells. AIDS Res Hum Retroviruses. 2001, 17: 59-68. 10.1089/088922201750056799.PubMed

171.

Ito Y, Grivel JC, Chen S, Kiselyeva Y, Reichelderfer P, Margolis L: CXCR4-tropic HIV-1 suppresses replication of CCR5-tropic HIV-1 in human lymphoid tissue by selective induction of CC-chemokines. J Infect Dis. 2004, 189: 506-514. 10.1086/381153.PubMed

172.

Lusso P, Earl PL, Sironi F, Santoro F, Ripamonti C, Scarlatti G, Longhi R, Berger EA, Burastero SE: Cryptic nature of a conserved, CD4-inducible V3 loop neutralization epitope in the native envelope glycoprotein oligomer of CCR5-restricted, but not CXCR4-using, primary human immunodeficiency virus type 1 strains. J Virol. 2005, 79: 6957-6968. 10.1128/JVI.79.11.6957-6968.2005.PubMedCentralPubMed

173.

Pastore C, Ramos A, Mosier DE: Intrinsic obstacles to human immunodeficiency virus type 1 coreceptor switching. J Virol. 2004, 78: 7565-7574. 10.1128/JVI.78.14.7565-7574.2004.PubMedCentralPubMed

174.

Kuhmann SE, Moore JP: The HIV-1 phenotype variants: deadly and deadlier. J VirEntry. 2005, 1: 4-16.

175.

Tscherning C, Alaeus A, Fredriksson R, Bjorndal A, Deng H, Littman DR, Fenyo EM, Albert J: Differences in chemokine coreceptor usage between genetic subtypes of HIV-1. Virology. 1998, 241: 181-188. 10.1006/viro.1997.8980.PubMed

176.

Lee HY, Giorgi EE, Keele BF, Gaschen B, Athreya GS, Salazar-Gonzalez JF, Pham KT, Goepfert PA, Kilby JM, Saag MS: Modeling sequence evolution in acute HIV-1 infection. J Theor Biol. 2009, 261: 341-360. 10.1016/j.jtbi.2009.07.038.PubMedCentralPubMed

177.

Keele BF, Giorgi EE, Salazar-Gonzalez JF, Decker JM, Pham KT, Salazar MG, Sun C, Grayson T, Wang S, Li H: Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proceedings of the National Academy of Sciences of the United States of America. 2008, 105: 7552-7557. 10.1073/pnas.0802203105.PubMedCentralPubMed

178.

Keele BF: Identifying and characterizing recently transmitted viruses. Curr Opin HIV AIDS. 2010, 5: 327-334. 10.1097/COH.0b013e32833a0b9b.PubMedCentralPubMed

179.

Li H, Bar KJ, Wang S, Decker JM, Chen Y, Sun C, Salazar-Gonzalez JF, Salazar MG, Learn GH, Morgan CJ: High Multiplicity Infection by HIV-1 in Men Who Have Sex with Men. PLoS Pathog. 2010, 6: e1000890-10.1371/journal.ppat.1000890.PubMedCentralPubMed

180.

Gupta P, Collins KB, Ratner D, Watkins S, Naus GJ, Landers DV, Patterson BK: Memory CD4(+) T cells are the earliest detectable human immunodeficiency virus type 1 (HIV-1)-infected cells in the female genital mucosal tissue during HIV-1 transmission in an organ culture system. Journal of virology. 2002, 76: 9868-9876. 10.1128/JVI.76.19.9868-9876.2002.PubMedCentralPubMed

181.

Peters PJ, Sullivan WM, Duenas-Decamp MJ, Bhattacharya J, Ankghuambom C, Brown R, Luzuriaga K, Bell J, Simmonds P, Ball J, Clapham PR: Non-macrophage-tropic human immunodeficiency virus type 1 R5 envelopes predominate in blood, lymph nodes, and semen: implications for transmission and pathogenesis. Journal of virology. 2006, 80: 6324-6332. 10.1128/JVI.02328-05.PubMedCentralPubMed

182.

Alexander M, Lynch R, Mulenga J, Allen S, Derdeyn CA, Hunter E: Donor and recipient envs from heterosexual human immunodeficiency virus subtype C transmission pairs require high receptor levels for entry. Journal of virology. 2010, 84: 4100-4104. 10.1128/JVI.02068-09.PubMedCentralPubMed

183.

Liu Y, Curlin ME, Diem K, Zhao H, Ghosh AK, Zhu H, Woodward AS, Maenza J, Stevens CE, Stekler J: Env length and N-linked glycosylation following transmission of human immunodeficiency virus Type 1 subtype B viruses. Virology. 2008, 374: 229-233. 10.1016/j.virol.2008.01.029.PubMedCentralPubMed

184.

Derdeyn CA, Decker JM, Bibollet-Ruche F, Mokili JL, Muldoon M, Denham SA, Heil ML, Kasolo F, Musonda R, Hahn BH: Envelope-constrained neutralization-sensitive HIV-1 after heterosexual transmission. Science. 2004, 303: 2019-2022. 10.1126/science.1093137.PubMed

185.

Doores KJ, Bonomelli C, Harvey DJ, Vasiljevic S, Dwek RA, Burton DR, Crispin M, Scanlan CN: Envelope glycans of immunodeficiency virions are almost entirely oligomannose antigens. Proceedings of the National Academy of Sciences of the United States of America. 2010

186.

Geijtenbeek TB, Kwon DS, Torensma R, van Vliet SJ, van Duijnhoven GC, Middel J, Cornelissen IL, Nottet HS, KewalRamani VN, Littman DR: DC-SIGN, a dendritic cell-specific HIV-1-binding protein that enhances trans-infection of T cells. Cell. 2000, 100: 587-597. 10.1016/S0092-8674(00)80694-7.PubMed

187.

Geijtenbeek TB, van Kooyk Y: DC-SIGN: a novel HIV receptor on DCs that mediates HIV-1 transmission. Curr Top Microbiol Immunol. 2003, 276: 31-54.PubMed

188.

Muratori C, Bona R, Ruggiero E, D'Ettorre G, Vullo V, Andreotti M, Federico M: DC contact with HIV-1-infected cells leads to high levels of Env-mediated virion endocytosis coupled with enhanced HIV-1 Ag presentation. Eur J Immunol. 2009, 39: 404-416. 10.1002/eji.200838751.PubMed

189.

van der Vlist M, Geijtenbeek TB: Langerin functions as an antiviral receptor on Langerhans cells. Immunol Cell Biol. 2010, 88: 410-415. 10.1038/icb.2010.32.PubMed

190.

Fauci AS: New Concepts in HIV/AIDS Pathogenesis: Implications for Interventions. In Book New Concepts in HIV/AIDS Pathogenesis: Implications for Interventions (Editor ed.^eds.), vol. TUPL010. City; 2010

191.

Cicala C, Martinelli E, McNally JP, Goode DJ, Gopaul R, Hiatt J, Jelicic K, Kottilil S, Macleod K, O'Shea A: The integrin {alpha}4{beta}7 forms a complex with cell-surface CD4 and defines a T-cell subset that is highly susceptible to infection by HIV-1. Proceedings of the National Academy of Sciences of the United States of America. 2009

192.

Brenchley JM, Douek DC: HIV infection and the gastrointestinal immune system. Mucosal Immunol. 2008, 1: 23-30. 10.1038/mi.2007.1.PubMedCentralPubMed

193.

Sagar M, Laeyendecker O, Lee S, Gamiel J, Wawer MJ, Gray RH, Serwadda D, Sewankambo NK, Shepherd JC, Toma J: Selection of HIV variants with signature genotypic characteristics during heterosexual transmission. J Infect Dis. 2009, 199: 580-589. 10.1086/596557.PubMedCentralPubMed

194.

Margolis L, Shattock R: Selective transmission of CCR5-utilizing HIV-1: the 'gatekeeper' problem resolved?. Nat Rev Microbiol. 2006, 4: 312-317. 10.1038/nrmicro1387.PubMed

Title: Selective transmission of R5 HIV-1 variants: where is the gatekeeper?
Authors: Jean-Charles Grivel
Robin J Shattock
Leonid B Margolis
Publication date: 01-12-2011
Publisher: BioMed Central
Published in: Journal of Translational Medicine / Issue Special Issue 1/2011
Electronic ISSN: 1479-5876
DOI: https://doi.org/10.1186/1479-5876-9-S1-S6

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Special Issue 1/2011

HIV-1 co-receptor usage:influence on mother-to-child transmission and pediatric infection

Clinical use of CCR5 inhibitors in HIV and beyond

Coreceptor use in nonhuman primate models of HIV infection

Conformational HIV-1 Envelope on particulate structures: a tool for chemokine coreceptor binding studies

Natural anti-CCR5 antibodies in HIV-infection and -exposure

HIV-1 envelope, integrins and co-receptor use in mucosal transmission of HIV

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage